The Oncologist

11/14/2025

chatbots🤖can create accurate treatment suggestions from data🧬. They may aid but not replace expert . Human oversight remains essential.
https://doi.org/10.1093/oncolo/oyaf316

11/13/2025

This tender explores shifts for facing voice loss. Expressive writing✍️, empathy, and clinician reflection foster and . It highlights that true connection and voice endure beyond words 🗣️
https://doi.org/10.1093/oncolo/oyaf289

11/12/2025

Concurrent RT/SRT with showed promising safety in patients with stage IV . Low acute (20%) & late (10%) toxicity was observed, with most non-hematologic AEs linked to RT & hematologic AEs likely due to T-DXd.

AbstractAim. This observational analysis, derived from the prospective mono-institutional COMBART cohort (stage IV breast cancer patients undergoing radiat

11/10/2025

Ph 2 trial of perioperative + + SBRT in resectable and borderline showed R0 resection in 45% and 31%, respectively. Median OS 22–39 mo

AbstractBackground. Surgical resection without visible or residual microscopic disease (R0 resection) is known as the optimal path to cure localized pancre

11/07/2025

A global 🌎 survey of 201 physicians found key concerns for use in advanced including neuropathy ⚡️ , ECOG ≥3, and high non-urothelial tumor content. Highlights need for guidance and risk stratification

AbstractBackground. Enfortumab vedotin combined with pembrolizumab (EV-P) has become the new standard first-line therapy for patients with advanced urothel

11/06/2025

In unresectable transhepatic PV/SMV stenting safely relieves venous stenosis. N=129 patients, 97% had technical success and 85% symptom relief, with 80% stent patency at 20 mo. A viable option for selected cases

AbstractImportance and Objective. Pancreatic cancer can lead to severe stenosis of the portomesenteric venous (PV/SMV) confluence due to extrinsic compress

11/05/2025

In metastatic , first-line dual outperformed both monotherapy and chemotherapy with manageable toxicity. Benefits were strongest in -sided or mutant tumors

AbstractBackground. Patients with deficient mismatch repair (dMMR) and/or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) show

11/04/2025

In adjuvant BRAF-mutant , + (D+T) improved recurrence-free survival vs. anti-PD(L)1 therapies (HR 0.53) but showed no OS benefit and had higher discontinuation risk. Treatment choice should be individualized.
https://doi.org/10.1093/oncolo/oyaf247

11/03/2025

In this retrospective study, –related toxicities were less frequent and less severe in private practice vs. university hospitals, but diagnosis was delayed and sequelae more common, underscoring the need to include community settings in real-world analyses.

AbstractBackground. Immune checkpoint inhibitors (ICIs) are widely used in cancer therapy, yet diagnosing and managing immune-related adverse events (irAEs

10/31/2025

Factors associated with sleep disturbance in breast cancer survivors over time

https://doi.org/10.1093/oncolo/oyaf297

10/28/2025

Introducing The Oncologist’s first eJournal Club!
This interactive event brings together authors, one of our Early Career Investigators, and our Social Media Editor to explore a featured study’s impact on oncology.
🗓️ Oct 30 | ⏰ 6–7pm EDT
Join us on X and follow !
Learn more: https://academic.oup.com/oncolo/pages/ejournal-club

10/27/2025

First real-world comparison of HLX02 vs reference trastuzumab (RTZ) and pertuzumab with chemotherapy as the first-line treatment for HER2-positive metastatic breast cancer (MBC) patients in China.
https://doi.org/10.1093/oncolo/oyaf183